Barclays Maintains Overweight on Medtronic, Raises Price Target to $120

Barclays analyst Matt Miksic has maintained an Overweight rating on Medtronic (NYSE: MDT) and raised the price target from $118 to $120. This adjustment reflects a positive outlook on the company's performance.